Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians.
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 34 of the 57 sources its claims cite were checked for support.
Abstract
Age-related macular degeneration (AMD) is a multifactorial genetic disease, with at least 52 identifiable associated gene variants at 34 loci, including variants in complement factor H (CFH) and age-related maculopathy susceptibility 2/high-temperature requirement A serine peptidase-1 (ARMS2/HTRA1). Genetic factors account for up to 70% of disease variability. However, population-based genetic risk scores are generally more helpful for clinical trial design and stratification of risk groups than for individual patient counseling. There is some evidence of pharmacogenetic influences on various treatment modalities used in AMD patients, including Age-Related Eye Disease Study (AREDS) supplements, photodynamic therapy (PDT), and anti-vascular endothelial growth factor (anti-VEGF) agents. However, there is currently no convincing evidence that genetic information plays a role in routine clinical care.
Overview
CoChat Summary
TL;DR
This narrative review summarizes age-related macular degeneration (AMD) genetics and pharmacogenetics, noting that AMD is highly polygenic with genetic factors accounting for up to 70% of disease variability. It concludes that genetic testing is not indicated in routine AMD care because pharmacogenetic associations remain inconsistent and largely unreplicated.
Key findings
- AMD has at least 52 independently associated variants across 34 loci, including CFH and ARMS2/HTRA1; the IAMDGC GWAS included 16,144 AMD patients and 17,832 controls, and a TWAS in the same cohorts reported 106 genes significantly associated with AMD in at least one tissue, including 28 in tibial nerve, 28 in subcutaneous adipose, and 26 in lung tissue.
- Pharmacogenetic associations have been reported for anti-VEGF agents, PDT, and AREDS/AREDS 2 nutritional supplementation, but findings are inconsistent: two large multicenter randomized clinical trials could not replicate anti-VEGF pharmacogenetic findings, and a 2022 review of 41 observational series, 7 meta-analyses, and 5 GWAS reported no consistent patterns.
- A 2022 meta-analysis of 33 case-control series concluded that variants at CFH, ARMS2/HTRA1, and OR52B4 were significantly associated with anti-VEGF response, while AREDS analyses conflicted: an initial retrospective analysis of 876 patients suggested CFH-related differences, but AREDS investigators could not replicate findings in a 526-participant residual cohort, and AREDS 2 investigators found no significant CFH/ARMS2 interaction in 1,684 patients.
- Population-based genetic risk scores are described as useful for clinical trial design and risk stratification, but not for individual patient counseling; the authors state there is no convincing evidence that genetic information improves routine clinical outcomes and that they do not use commercially available AMD genetic testing in practice.
Methods
- Design: narrative review for clinicians, not a systematic review or meta-analysis.
- Data: cited literature on AMD genetics and pharmacogenetics, including GWAS, TWAS, randomized trials, observational series, meta-analyses, and a selected recent pharmacogenetic association table.
- Analysis: narrative synthesis of reported genetic associations and clinical implications, with no formal search strategy, quality appraisal, or primary data analysis described.
Limitations
- Stated: pharmacogenetic results are inconsistent and frequently conflicting, potentially due to baseline population differences, small sample sizes, heterogeneous treatment protocols, and differences in outcome measures; the paper notes that at least 15,000 patients may be needed to definitively identify genetic associations with anti-VEGF response.
- Stated: there is currently no convincing evidence that using genetic information improves clinical outcomes, and no indication to perform genetic sequencing on patients with AMD.
- Evident: as a narrative review, it relies on selected studies and a selected table rather than a systematic literature search, and it does not provide new primary data or formal risk-of-bias assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Valid · 1 Not valid · 12 Not checked · 6 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Variants in methylenetetrahydrofolate reductase (MTHFR) were associated with more PDT sessions [59].”
§ Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians > 3.2 Photodynamic Therapy
What the sources say
- Disputedcites [59] Parmeggiani F, Gallenga CE, Costagliola C, Semeraro F, Romano MR, Dell’Omo R, et al. Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration. Scientific Reports. 2019; 9: 2614. sourceExperimental — accuracy not yet measured
The Results report fewer PDT-V treatments over 24 months for patients with the MTHFR-C677T CT and TT genotypes (means of 4.1 and 3.5) than for those with the wild-type CC genotype (5.4). The Discussion likewise says the variant genotypes predicted a lower probability of needing more treatments, contrary to the claim. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Unlike a monogenic (Mendelian) disease, AMD heritability is not controlled by a single mutation that can be identified from a pedigree analysis and observed in a family line [18,19].”
§ Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians > 2. AMD Genetics
What the sources say
- Partly supportedcites [18] De Rycke M, Berckmoes V. Preimplantation Genetic Testing for Monogenic Disorders. Genes. 2020; 11: 871. sourceExperimental — accuracy not yet measured
The Abstract and §2, “Indications for PGT-M,” describe monogenic disorders as having identifiable disease-causing loci; §5.3 describes tracing pathogenic variants using family-based haplotyping. These passages support the sentence’s contrast with monogenic disease, but the paper does not address AMD or establish that AMD heritability is not controlled by a single mutation. (LLM, conf=0.86)
- Partly supportedcites [19] Muse ED, Chen SF, Torkamani A. Monogenic and Polygenic Models of Coronary Artery Disease. Current Cardiology Reports. 2021; 23: 107. sourceExperimental — accuracy not yet measured
The Introduction’s “Heritability of CAD” section describes monogenic diseases as resulting from a single-gene mutation, and the familial hypercholesterolemia section discusses identifying mutations through family studies and testing relatives. The paper addresses coronary artery disease, not AMD, so it does not establish the AMD-specific claim about heritability or pedigree analysis. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, a series of 196 patients with geographic atrophy were classified into three distinct subgroups largely by genetic risk scores [28].”
§ Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians > 2. AMD Genetics
What the sources say
- Supportedcites [28] Biarnés M, Colijn JM, Sousa J, Ferraro LL, Garcia M, Verzijden T, et al. Genotype- and Phenotype-Based Subgroups in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology. Retina. 2020; 4: 1129–1137. source
The Abstract identifies 196 eyes from 196 patients with geographic atrophy and reports three subgroups. The Discussion says the subgroups were driven largely by genetic risk scores, although fundus features were also used in the clustering. (LLM, conf=0.94)
plainstates an associationn = 196- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Other genes involving the complement cascade, lipid metabolism, extracellular matrix, and immune function have also been associated with AMD [1,17].”
§ Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians > 2. AMD Genetics
What the sources say
- Supportedcites [1] Stradiotto E, Allegrini D, Fossati G, Raimondi R, Sorrentino T, Tripepi D, et al. Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential. International Journal of Molecular Sciences. 2022; 23: 13280. source
Section 3.1, “AMD Genomics” (page unavailable), reports AMD-associated variants in complement and lipid-metabolism genes. Its “Immune Response and Complement Genes” and “Extracellular Matrix Alterations” subsections also discuss immune-related and extracellular-matrix genes linked to AMD. (LLM, conf=0.92)
- Supportedcites [17] Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature Genetics. 2016; 48: 134–143. source
The Results section reports AMD-associated loci containing extracellular-matrix, lipid-metabolism, and immune-function genes. It also identifies associated variants in or near complement genes, supporting the fourth category. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There is some evidence of pharmacogenetic influences on various treatment modalities used in AMD patients, including Age-Related Eye Disease Study (AREDS) supplements, photodynamic therapy (PDT), and anti-vascular endothelial growth factor (anti-VEGF) agents.”
- Also stated in: § 1. Introduction · plain
“Notably, there is evidence of a pharmacogenetic effect on many of these interventions [15,16].”
§ Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians > Abstract
What the sources say
- Supportedcites [15] Hampton BM, Kovach JL, Schwartz SG. Pharmacogenetics and nutritional supplementation in age-related macular degeneration. Clinical Ophthalmology (Auckland, N.Z.). 2015; 9: 873–876. source
The Introduction reports a potential pharmacogenetic component to AREDS response and says small case series found associations between genetic variants and outcomes with PDT and anti-VEGF therapy. It also notes that two large trials found no statistically significant associations for the latter treatments, consistent with the claim’s cautious wording, “some evidence.” (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [16] Schwartz SG, Brantley MA, Kovach JL, Grzybowski A. Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration. Current Pharmaceutical Design. 2017; 23: 547–550. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
27 more claims · 14 with their cited sources checked
Create a free account to see all 43 claims and every source verdict.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 2
- The quote only partly states this claim. 2
Citations
Cites
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Fritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., Burdon, K. P., Hebbring, S. J., Wen, C., Gorski, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3448 · Cited by 1,544 · cited 7×
“Other genes involving the complement cascade, lipid metabolism, extracellular matrix, and immune function have also been associated with AMD [1,17].”
BackgroundInfluentialDeng, Y., Qiao, L., Du, M., Qu, C., Wan, L., Li, J., & Huang, L. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.02.009 · Cited by 411 · cited 3×
“Genes involving at least 25 different biological functions have been reported as being associated with AMD, of which the complement pathways have been studied most intensively [ 24].”
BackgroundVerteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia
(2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01998-x · Cited by 354 · cited 1×
“Photodynamic therapy (PDT) with verteporfin (Visu-dyne, Bausch, and Lomb) has been supplanted by anti-VEGF therapy but is occasionally used in the treatment of individual patients [46–49].”
BackgroundDo blue light filters confer protection against age-related macular degeneration?
MARGRAIN, T. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.05.001 · Cited by 257
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.4.448 · Cited by 192
Klein, M. L., Francis, P. J., Rosner, B., Reynolds, R., Hamon, S. C., Schultz, D. W., Ott, J., & Seddon, J. M. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.01.036 · Cited by 172 · cited 1×
“A retrospective analysis of 876 patients from AREDS reported that more favorable outcomes were associated with no risk alleles at CFH than with two risk alleles at CFH [60].”
BackgroundBressler, N. M. (2001) · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · Cited by 170
Mediterranean Diet and Incidence of Advanced Age-Related Macular Degeneration
Merle, B. M. J., Colijn, J. M., Cougnard-Grégoire, A., de Koning-Backus, A. P. M., Delyfer, M.-N., Kiefte-de Jong, J. C., Meester-Smoor, M., Féart, C., Verzijden, T., Samieri, C., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.08.006 · Cited by 169
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142 · cited 1×
“However, two large, multicenter randomized clinical trials could not replicate these findings [36,37].”
BackgroundPreimplantation Genetic Testing for Monogenic Disorders
De Rycke, M., & Berckmoes, V. (2020) · Genes · doi:10.3390/genes11080871 · Cited by 140 · cited 1×
“Unlike a monogenic (Mendelian) disease, AMD heritability is not controlled by a single mutation that can be identified from a pedigree analysis and observed in a family line [ 18,19].”
BackgroundAwh, C. C., Lane, A. M., Hawken, S., Zanke, B. W., & Kim, I. K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.039 · Cited by 127
Chong, E. W.-T., Kreis, A. J., Wong, T. Y., Simpson, J. A., & Guymer, R. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.005 · Cited by 112
Implementation and utilization of genetic testing in personalized medicine
Scott, S., Abul-Husn, N., Owusu Obeng, A., Sanderson, S., & Gottesman, O. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s48887 · Cited by 106
Awh, C. C., Hawken, S., & Zanke, B. W. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.049 · Cited by 96
Chew, E. Y., Klein, M. L., Clemons, T. E., Agrón, E., Ratnapriya, R., Edwards, A. O., Fritsche, L. G., Swaroop, A., & Abecasis, G. R. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.008 · Cited by 94 · cited 1×
“The AREDS investigators reported that they could not replicate the findings, concluding that no significant associations existed [64,65].”
BackgroundAbedi, F., Wickremasinghe, S., Richardson, A. J., Makalic, E., Schmidt, D. F., Sandhu, S. S., Baird, P. N., & Guymer, R. H. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.006 · Cited by 85
Towards the application of precision medicine in Age-Related Macular Degeneration
Cascella, R., Strafella, C., Caputo, V., Errichiello, V., Zampatti, S., Milano, F., Potenza, S., Mauriello, S., Novelli, G., Ricci, F., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.004 · Cited by 76 · cited 2×
“Up to 70% of the clinical variability in AMD can be explained by genetic variants [1,17,20], meaning this disease may be amenable to personalized medical approaches.”
BackgroundTWAS results are complementary to and less affected by linkage disequilibrium than GWAS
Li, D., Liu, Q., & Schnable, P. S. (2021) · Plant Physiology · doi:10.1093/plphys/kiab161 · Cited by 71 · cited 1×
“A transcriptome-wide association study (TWAS) can identify associations between gene expression levels and disease states [29].”
BackgroundGao, Y., Yu, T., Zhang, Y., & Dang, G. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23747 · Cited by 68
Genetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67 · cited 1×
“The ability to better risk-stratify patients can improve outcomes by better allocating scarce resources to the patients most in need or by selecting the most effective treatment from alternatives [1,26].”
BackgroundVavvas, D. G., Small, K. W., Awh, C. C., Zanke, B. W., Tibshirani, R. J., & Kustra, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718059115 · Cited by 67 · cited 1×
“Based on these results, these investigators recommended using genotype-directed nutritional supplementation for routine clinical care [ 61–63].”
Moon, B., Kim, Y., & Kim, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613004 · Cited by 65 · cited 1×
“Patients with neovascular (exudative) AMD are generally treated with intravitreal injections of an anti-vascular endothelial growth factor (anti-VEGF) agent [12].”
BackgroundRastogi, N., & Smith, R. T. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.10.003 · Cited by 63 · cited 1×
“The pathogenesis of AMD is influenced by both modifiable (dietary choices, smoking) and non-modifiable (age, genetic variants) factors [1–9].”
BackgroundChew, E. Y., Klein, M. L., Clemons, T. E., Agrón, E., & Abecasis, G. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.10.012 · Cited by 61 · cited 1×
“The AREDS investigators reported that they could not replicate the findings, concluding that no significant associations existed [64,65].”
BackgroundStrunz, T., Lauwen, S., Kiel, C., International AMD Genomics Consortium (IAMDGC), Fritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58510-9 · Cited by 60 · cited 1×
“…a transcriptome-wide association study (TWAS) of 16,144 AMD patients and 17,832 controls and reported 106 genes significantly associated with AMD variants in at least one tissue, including 28 genes in tibial nerve tissue, 28 genes in subcutaneous adipose tissue, and 26 genes in lung tissue [30].”
BackgroundSelf-citationLong-Term Blood Pressure and Age-Related Macular Degeneration: The ALIENOR Study
Cougnard-Grégoire, A., Delyfer, M.-N., Korobelnik, J.-F., Rougier, M.-B., Malet, F., Le Goff, M., Dartigues, J.-F., Colin, J., Barberger-Gateau, P., & Delcourt, C. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10192 · Cited by 56
Feng, X., Xiao, J., Longville, B., Tan, A. X. J., Wu, X. N., Cooper, M. N., McAllister, I. L., Isaacs, T., Palmer, L. J., & Constable, I. J. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.011 · Cited by 54 · cited 1×
“Common variants at CFH were reported not to be associated with PDT outcomes [54,55], whereas variants at the vascular endothelial growth factor ( VEGF ) and C-reactive protein ( CRP ) were reported to be associated with improved outcomes after PDT [55,56].”
BackgroundPan, Y., Fu, Y., Baird, P. N., Guymer, R. H., Das, T., & Iwata, T. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101159 · Cited by 50 · cited 1×
“In-deed, the most common loci confirmed in multiple studies are complement factor H ( CFH ) and age-related mac-ulopathy susceptibility 2/high-temperature requirement A serine peptidase-1 ( ARMS2/HTRA1 ); the latter two variants are strongly associated by linkage disequilibrium [17, 24–27].”
BackgroundThe complement system: a novel therapeutic target for age-related macular degeneration
Shughoury, A., Sevgi, D. D., & Ciulla, T. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2257604 · Cited by 50 · cited 1×
“Patients with geographic atrophy were traditionally observed, although two intravitreal complement inhibitors have recently achieved FDA approval in the US: Pegcetacoplan (Syfovre, Apellis Pharmaceuticals) and avacincaptad pegol (Izervay, Astellas Pharmaceuticals) [14].”
BackgroundSeitsonen, S. P., Järvelä, I. E., Meri, S., Tommila, P. V., Ranta, P. H., & Immonen, I. J. (2007) · European Journal of Ophthalmology · doi:10.1177/112067210701700612 · Cited by 48
Assel, M. J., Li, F., Wang, Y., Allen, A. S., Baggerly, K. A., & Vickers, A. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.09.008 · Cited by 48 · cited 1×
“Additional investigators independently reviewed the AREDS data and concluded that no significant genetic associations existed [66].”
BackgroundImmonen, I., Seitsonen, S., Tommila, P., Kangas-Kontio, T., Kakko, S., Savolainen, E.-R., Savolainen, M. J., & Liinamaa, M. J. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.037 · Cited by 45 · cited 1×
“Common variants at CFH were reported not to be associated with PDT outcomes [54,55], whereas variants at the vascular endothelial growth factor ( VEGF ) and C-reactive protein ( CRP ) were reported to be associated with improved outcomes after PDT [55,56].”
BackgroundFauser, S., & Lambrou, G. N. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.11.002 · Cited by 41
Biarnés, M., Colijn, J. M., Sousa, J., Ferraro, L. L., Garcia, M., Verzijden, T., Meester-Smoor, M. A., Delcourt, C., Klaver, C. C. W., den Hollander, A. I., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.04.014 · Cited by 40 · cited 1×
“However, a series of 196 patients with geographic atrophy were classified into three distinct subgroups largely by genetic risk scores [28].”
BackgroundBoltz, A., Ruiß, M., Jonas, J. B., Tao, Y. K., Rensch, F., Weger, M., Garhöfer, G., Frantal, S., El‐Shabrawi, Y., & Schmetterer, L. F. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.001 · Cited by 40
Zhao, L., Grob, S., Avery, R., Kimura, A., Pieramici, D., Lee, J., Rabena, M., Ortiz, S., Quach, J., Cao, G., et al. (2013) · Current Molecular Medicine · doi:10.2174/15665240113139990048 · Cited by 39 · cited 1×
“Various series have reported statistically significant associations in treatment outcomes (including anatomic factors and visual acuity improvement) with variants at CFH , ARMS2/HTRA1 , and other genes following treatment with bevacizumab, ranibizumab, and aflibercept [31–35].”
BackgroundPredicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration
van Asten, F., Rovers, M. M., Lechanteur, Y. T. E., Smailhodzic, D., Muether, P. S., Chen, J., den Hollander, A. I., Fauser, S., Hoyng, C. B., van der Wilt, G. J., et al. (2014) · Ophthalmic Epidemiology · doi:10.3109/09286586.2014.949010 · Cited by 37 · cited 1×
“There is substantial interpatient variability in the treat-ment response, and individual patients appear to respond better to different anti-VEGF agents, which suggests a pharmacogenetic effect [31,32].”
BackgroundHagstrom, S. A., Ying, G.-S., Maguire, M. G., Martin, D. F., Gibson, J., Lotery, A., & Chakravarthy, U. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.04.024 · Cited by 37 · cited 1×
“However, two large, multicenter randomized clinical trials could not replicate these findings [36,37].”
BackgroundKim, E., Kim, H., Vijayakumar, A., Kwon, O., & Chang, N. (2017) · Nutrition Journal · doi:10.1186/s12937-017-0301-2 · Cited by 37 · cited 1×
“AMD-related polygenic patterns require population-based analysis and may vary between different populations [17,20–23].”
BackgroundAdherence to a Mediterranean Diet and Geographic Atrophy Enlargement Rate
Agrón, E., Mares, J. A., Chew, E. Y., & Keenan, T. D. L. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.022 · Cited by 36
May, A., Su, F., Dinh, B., Ehlen, R., Tran, C., Adivikolanu, H., & Shaw, P. X. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108605 · Cited by 34
Gastaldello, A., Giampieri, F., Quiles, J. L., Navarro‐Hortal, M. D., Obregón, S. A., Villena, E. G., Pifarré, K. T., Giuseppe, R. D., Grosso, G., Cianciosi, D., et al. (2022) · Nutrients · doi:10.3390/nu14102028 · Cited by 33
Spielberg, L., & Leys, A. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1256-6 · Cited by 31 · cited 2×
“Currently, PDT may be offered in combination with anti-VEGF [50,51] or to “rescue” poor responders [13,52,53].”
BackgroundGenetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113280 · Cited by 29 · cited 5×
“The ability to better risk-stratify patients can improve outcomes by better allocating scarce resources to the patients most in need or by selecting the most effective treatment from alternatives [1,26].”
BackgroundInfluentialvan Asten, F., Chiu, C.-Y., Agrón, E., Clemons, T. E., Ratnapriya, R., Swaroop, A., Klein, M. L., Fan, R., & Chew, E. Y. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.004 · Cited by 27 · cited 1×
“Subsequently, the AREDS 2 investigators performed a retrospective analysis of 1684 patients from AREDS 2 (as opposed to AREDS) and reported no significant association between CFH , ARMS2 , and the response to nutritional supplements [67].”
MethodMonogenic and Polygenic Models of Coronary Artery Disease
Muse, E. D., Chen, S.-F., & Torkamani, A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01540-0 · Cited by 27 · cited 1×
“Unlike a monogenic (Mendelian) disease, AMD heritability is not controlled by a single mutation that can be identified from a pedigree analysis and observed in a family line [ 18,19].”
BackgroundRiaz, M., Lorés-Motta, L., Richardson, A. J., Lu, Y., Montgomery, G., Omar, A., Koenekoop, R. K., Chen, J., Muether, P., Altay, L., et al. (2016) · Scientific Reports · doi:10.1038/srep37924 · Cited by 26
Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment
Oca, A. I., Pérez-Sala, Á., Pariente, A., Ochoa, R., Velilla, S., Peláez, R., & Larráyoz, I. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121329 · Cited by 25 · cited 1×
“Transcriptome analysis of peripheral blood mononuclear cells from 59 patients treated with ranibizumab demonstrated that the ranibizumab response could be predicted before treatment [39].”
BackgroundWang, Z., Zou, M., Chen, A., Liu, Z., Young, C. A., Wang, S., Zheng, D., & Jin, G. (2022) · Acta Ophthalmologica · doi:10.1111/aos.14970 · Cited by 22 · cited 1×
“A 2022 meta-analysis of 33 case–control series concluded that variants at CFH , ARMS2/HTRA1 , and olfactory receptor family 52 subfamily B member 4 ( OR52B4 ) were significantly associated with the clinical response to anti-VEGF agents [38].”
BackgroundMataix, J., Palacios, E., Desco, C., García-Pous, M., & Návea, A. (2010) · Retina · doi:10.1097/iae.0b013e3181d2f172 · Cited by 17 · cited 1×
“Currently, PDT may be offered in combination with anti-VEGF [50,51] or to “rescue” poor responders [13,52,53].”
BackgroundGenetic risk factors for late age-related macular degeneration in India
Rajendran, A., Dhoble, P., Sundaresan, P., Vijayan, S., Vashist, P., Nitsch, D., Smeeth, L. L., Chakravarthy, U., Ravindran, R. D., & FLETCHER, A. E. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311384 · Cited by 17
Kubicka‐Trząska, A., Żuber-Łaskawiec, K., Dziedzina, S., Sanak, M., Romanowska‐Dixon, B., & Karska‐Basta, I. (2022) · Medicina · doi:10.3390/medicina58050658 · Cited by 17 · cited 1×
“[31–45]) demonstrates the variable findings reported in the selected recent series.”
BackgroundYoshida, M., Oishi, A., Miyake, M., Ooto, S., Tamura, H., Miyata, M., Takahashi, A., Hata, M., Yamashiro, K., & Tsujikawa, A. (2022) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2022.102745 · Cited by 14 · cited 2×
“Currently, PDT may be offered in combination with anti-VEGF [50,51] or to “rescue” poor responders [13,52,53].”
BackgroundWada, I., Shiose, S., Ishikawa, K., Kano, K., Notomi, S., Mori, K., Akiyama, M., Nakao, S., & Sonoda, K. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05553-5 · Cited by 14 · cited 1×
“Currently, PDT may be offered in combination with anti-VEGF [50,51] or to “rescue” poor responders [13,52,53].”
BackgroundMaking Biological Sense of Genetic Studies of Age-Related Macular Degeneration
Singh, N., Swaroop, A., & Ratnapriya, R. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-66014-7_8 · Cited by 11
Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
Chaudhary, V., Brent, M., Lam, W.-C., Devenyi, R., Teichman, J., Mak, M., Barbosa, J., Kaur, H., Carter, R., & Farrokhyar, F. (2016) · Ophthalmologica · doi:10.1159/000446819 · Cited by 10 · cited 3×
“Various series have reported statistically significant associations in treatment outcomes (including anatomic factors and visual acuity improvement) with variants at CFH , ARMS2/HTRA1 , and other genes following treatment with bevacizumab, ranibizumab, and aflibercept [31–35].”
BackgroundStrunz, T., Pöllmann, M., Gamulescu, M.-A., Tamm, S., & Weber, B. H. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116094 · Cited by 10 · cited 2×
“It has been suggested that a sample size of at least 15,000 patients would be necessary to definitively identify genetic associations with responses to anti-VEGF therapy [40].”
BackgroundPharmacogenetics and nutritional supplementation in age-related macular degeneration
Schwartz, S., Hampton, B., & Kovach, J. (2015) · Clinical Ophthalmology · doi:10.2147/opth.s84155 · Cited by 9 · cited 1×
“Notably, there is evidence of a pharmacogenetic effect on many of these interventions [15,16].”
BackgroundSelf-citationMockutė, R., Vilkevičiūtė, A., Balčiūnienė, V. J., Žemaitienė, R., & Liutkevičienė, R. (2021) · Medicina · doi:10.3390/medicina57090974 · Cited by 8
Preimplantation Genetic Testing for Monogenic Disorders
Rycke, M. D., & Verdyck, P. (2020) · CRC Press eBooks · doi:10.1201/9780429445972-5 · Cited by 8
Parmeggiani, F., Gallenga, C. E., Costagliola, C., Semeraro, F., Romano, M. R., Dell’Omo, R., Russo, A., De Nadai, K., Gemmati, D., D’Angelo, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38919-7 · Cited by 7 · cited 1×
“Variants at ARMS2/HTRA1 have been reported to have no significant association [57] or less favorable outcomes [58] after PDT. Variants in methylenetetrahydrofolate reductase ( MTHFR ) were associated with more PDT sessions [59].”
BackgroundHot Topics in Pharmacogenetics of Age-Related Macular Degeneration
Grzybowski, A., Kovach, J., Brantley, M., & Schwartz, S. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161208114847 · Cited by 4 · cited 1×
“Notably, there is evidence of a pharmacogenetic effect on many of these interventions [15,16].”
BackgroundSelf-citationHuang, Q., & Xiang, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.906298 · Cited by 3
Kaufman, S. R., Yoganathan, P., Small, K. W., Rusia, D., Pachydaki, S. I., Conti, S. M., Wenz, R. E., Gersman, M. A., Shaya, F. S., & Kustra, R. (2021) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420941713 · Cited by 1 · cited 1×
“More recently, a case-only series of 265 patients with neovascular AMD (not analyzed in AREDS or AREDS 2) using an AREDS formulation also reported an interaction between CFH , ARMS2 , and clinical outcomes [68].”
BackgroundDo blue light filters confer protection against age-related macular degeneration?
Margrain, T. H., Boulton, M., Marshall, J., et al. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.12.037
Research works printed but not linked: 2
- Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Molecular Vision. 2010; 16: 2598–2604.
- Nakai S, Honda S, Matsumiya W, Miki A, Nakamura M. ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration. Molecular Vision. 2017; 23: 514–519.
Cited by
Integrative Landscape of Dry AMD Pathogenesis, Models, and Emerging Therapeutic Strategies
Bhandari, S. K., Lee, S., & Kim, H. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010202 · Cited by 13
“Decrease in CFH level and variants increases risk of advanced AMD and drusen formation [29] Early macular drusen [30] To evaluate genetic risk and guide advanced AMD treatment strategies [31] Genetic testing not advised for routine patient counseling [32]”
Linking the microbiome to the complement system in geographic atrophy
Spörri, L. A., Studer, J. M., Kreuzer, M., Rotzetter, J., Schärer, D., Largiadèr, C. R., Jaggi, D., Zinkernagel, M. S., & Zysset‐Burri, D. C. (2026) · npj Genomic Medicine · doi:10.1038/s41525-026-00550-7 · Cited by 4
Zhou, Y., Wang, Z., Huang, C., Yu, X., Cai, X., Zhao, D., & Cai, Y. (2025) · Biogerontology · doi:10.1007/s10522-025-10329-5 · Cited by 4
“…research on genetic susceptibility has identified numerous risk loci with AMD, including polymorphisms in the complement factor H (CFH), age-related maculopathy susceptibility 2/ high-temperature requirement A serine peptidase–1 (ARMS2/HTRA1), and apolipoprotein E (APOE) genes (Nguyen et al. 2024).”
Zhang, P.-W., Wan, Z.-H., Liu, S., Wang, J., Sripathi, S. R., Li, W., Ahn, J., Li, S., Fan, L., Berlinicke, C. A., et al. (2025) · medRxiv · doi:10.1101/2025.10.29.25338834 · Cited by 3
Fujii, R., Matsushita, M., Itani, Y., Hama, A. T., Natsume, T., & Takamatsu, H. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70052 · Cited by 4
Metadata
- Authors
- Nguyen, J., Brantley, & Schwartz, S. G.
- Affiliations
- Rutgers New Jersey Medical School (US)
- Vanderbilt University Medical Center (US)
- University of Miami (US)
- Corresponding author
- Schwartz, Stephen G
- Venue
- Frontiers in Bioscience-Scholar
- Publisher
- IMR Press
- Published
- 2024-02-29
- Volume
- 16
- Issue
- 1
- Pages
- 3-3
- ISSN
- 1944-7906 (ISSN-L)
- 1945-0516
- 1945-0524
- OpenAlex
- W4392366336
- Cited by
- 12
- References
- 68
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 2
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Bioscience-Scholar (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIH Core Center (P30EY014801)
- Research to Prevent Blindness-Unrestricted (GR004596-1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, genetic susceptibility, genetic susceptibility loci, complement factor H, polygenic risk score, pharmacogenetics, photodynamic therapy, anti-VEGF therapy, patient counseling
- MeSH terms
- High-Temperature Requirement A Serine Peptidase 1, Humans, Macular Degeneration, Proteins, Risk Factors, Dietary Supplements, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.